Compared to SD and PD patients, a higher percentage of PD-L1+ CD14+ cells PLTneg in an NSCLC patient was considered a protective factor, significantly increasing the probability of responding to anti-PD-(L)1 therapy. The gene discussed is CD14; the disease is non-small cell lung carcinoma.